Analyst Reco. Tectonic Therapeutic, Inc.

Equities

AVRO

US8789721086

Real-time Estimate Cboe BZX Other stock markets 15:34:30 2024-06-27 EDT			5-day change	1st Jan Change
16.4 ^USD	+2.92%		-6.51%	-2.39%

06-20	Avrobio Closes Merger With Tectonic Therapeutic	MT
06-20	Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing	05-15	MT
Mizuho Securities Cuts Avrobio Price Target to $2 From $5, Buy Rating Kept	12-18	MT
Wells Fargo Adjusts Price Target on AVROBIO to $2 From $2.50, Maintains Overweight Rating	23-07-13	MT
Wedbush Downgrades AVROBIO to Neutral From Outperform on Halted Development of Gene Therapy Programs, Exploring Alternatives; PT is $2	23-07-12	MT
Wedbush Trims AVROBIO's PT to $2 From $4 on Heels of Announced Sale of Cystinosis Gene Therapy Program to Novartis, Keeps Outperform Rating	23-05-22	MT
Mizuho Adjusts Price Target on AVROBIO to $5 From $6, Keeps Buy Rating	23-03-24	MT
BTIG Upgrades AVROBIO to Buy From Neutral, Price Target is $4	22-12-08	MT
Needham Adjusts AVROBIO's Price Target to $6 from $8, Keeps Buy Rating	22-05-17	MT
Barclays Adjusts AVROBIO's Price Target to $4 from $6, Keeps Overweight Rating	22-05-11	MT
Morgan Stanley Adjusts AVROBIO's Price Target to $2 From $3, Maintains Equalweight Rating	22-02-01	MT
Mizuho Adjusts AVROBIO's Price Target to $6 from $28, Keeps Buy Rating	22-01-06	MT
Morgan Stanley Adjusts Price Target on AVROBIO to $3 From $7, Maintains Equal-Weight Rating	22-01-05	MT
Needham Adjusts AVROBIO's Price Target to $8 From $28, Reiterates Buy Rating	22-01-05	MT
BTIG Downgrades AVROBIO to Neutral From Buy	22-01-05	MT
Barclays Adjusts AVROBIO's Price Target to $6 From $22, Reiterates Overweight Rating	22-01-05	MT
Wedbush Lowers PT for AVROBIO to $14 From $30 As Company 'Deprioritizes' Fabry Disease Program, Maintains Outperform Rating	22-01-04	MT
Morgan Stanley Downgrades AVROBIO to Equal-Weight From Overweight, Adjusts Price Target to $7 From $24	21-11-19	MT
AVROBIO : Morgan Stanley Adjusts AVROBIO's Price Target to $25 from $27, Keeps Overweight Rating	21-10-12	MT
AVROBIO : Morgan Stanley Adjusts Price Target on AVROBIO to $29 From $31, Maintains Overweight Rating	21-07-16	MT
AVROBIO : BTIG Starts AVROBIO at Buy With $23 Price Target	21-06-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Tectonic Therapeutic, Inc.

Equities

AVRO

US8789721086

Analyst Reco.

Filters